Akebia Therapeutics (AKBA) News Today $2.07 +0.14 (+7.25%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period What is HC Wainwright's Estimate for AKBA FY2029 Earnings?January 18 at 3:25 AM | americanbankingnews.comFY2024 Earnings Estimate for AKBA Issued By HC WainwrightAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical companyJanuary 18 at 1:33 AM | marketbeat.comBrokers Set Expectations for AKBA FY2024 EarningsAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities researchers at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Akebia Therapeutics in a report issued on Tuesday, January 14th. HC Wainwright analyst E. Arce expects that the biopharmaceutical compJanuary 17 at 7:05 AM | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Increase in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 16,680,000 shares, a growth of 18.6% from the December 15th total of 14,070,000 shares. Based on an average daily volume of 2,100,000 shares, the short-interest ratio is currently 7.9 days.January 17 at 5:19 AM | marketbeat.comWhat is HC Wainwright's Forecast for AKBA FY2029 Earnings?Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical coJanuary 17 at 2:39 AM | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Downgraded to "Sell" Rating by StockNews.comJanuary 17 at 2:03 AM | americanbankingnews.comFY2029 Earnings Forecast for AKBA Issued By HC WainwrightAkebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - HC Wainwright issued their FY2029 earnings per share estimates for Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce anticipates that the biopharmaceutical company will post earnings peJanuary 16 at 7:47 AM | marketbeat.comStockNews.com Downgrades Akebia Therapeutics (NASDAQ:AKBA) to SellStockNews.com lowered shares of Akebia Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday.January 15 at 2:18 AM | marketbeat.comAkebia Therapeutics: Strong Market Position and Growth Potential Justifies Buy RatingJanuary 14, 2025 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.50 target price on shares of Akebia Therapeutics in a research note on Tuesday.January 14, 2025 | marketbeat.comAkebia announces ‘multiple positive business updates’January 13, 2025 | markets.businessinsider.comAkebia Therapeutics Announces Multiple Positive Business UpdatesJanuary 13, 2025 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded to "Hold" at StockNews.comJanuary 8, 2025 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold RatingStockNews.com raised Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday.January 7, 2025 | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 2, 2025 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.comStockNews.com cut Akebia Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday.December 30, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street CorpState Street Corp raised its position in shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 24.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,430,527 shares of the biopharmaceutical cDecember 30, 2024 | marketbeat.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Large Growth in Short InterestAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) saw a large increase in short interest in December. As of December 15th, there was short interest totalling 14,070,000 shares, an increase of 21.7% from the November 30th total of 11,560,000 shares. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is currently 7.1 days.December 29, 2024 | marketbeat.com404,718 Shares in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Acquired by Wellington Management Group LLPWellington Management Group LLP purchased a new stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 404,718 shares of the biopharmaceutical compaDecember 21, 2024 | marketbeat.comInvestors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five yearsDecember 21, 2024 | uk.finance.yahoo.comInvestors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five yearsDecember 21, 2024 | uk.finance.yahoo.comAkebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | prnewswire.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Friday.December 13, 2024 | marketbeat.comAkebia: U.S. Renal Care enrolls first patient in its VOICE collaborative trialDecember 3, 2024 | markets.businessinsider.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 3, 2024 | prnewswire.comU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on DialysisDecember 3, 2024 | prnewswire.comAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 25, 2024 | prnewswire.comQ3 2024 Earnings: Hold Akebia TherapeuticsNovember 20, 2024 | seekingalpha.comPiper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)November 14, 2024 | markets.businessinsider.comVadadustat Alternative Dosing Study Results Published in the American Journal of Kidney DiseaseNovember 14, 2024 | prnewswire.comAkebia Therapeutics to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | prnewswire.comAkebia Therapeutics Prepares for Vafseo LaunchNovember 10, 2024 | markets.businessinsider.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50November 10, 2024 | finance.yahoo.comAkebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...November 8, 2024 | finance.yahoo.comAkebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comAkebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNovember 7, 2024 | prnewswire.comAkebia Q3 2024 Earnings PreviewNovember 6, 2024 | msn.comAkebia Therapeutics (AKBA) Set to Announce Earnings on ThursdayAkebia Therapeutics (NASDAQ:AKBA) will be releasing earnings before the market opens on Thursday, November 7, Zacks reports.November 2, 2024 | marketbeat.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | prnewswire.comAkebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business HighlightsNovember 1, 2024 | prnewswire.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in OctoberAkebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totalling 17,680,000 shares, a decline of 6.0% from the September 30th total of 18,800,000 shares. Based on an average daily volume of 1,670,000 shares, the days-to-cover ratio is presently 10.6 days.October 31, 2024 | marketbeat.comAkebia Therapeutics: Strategic Developments and Financial Outlook Drive Buy RatingOctober 23, 2024 | markets.businessinsider.comAkebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.50 price target on shares of Akebia Therapeutics in a research report on Wednesday.October 23, 2024 | marketbeat.comAkebia signs commercial supply contract with dialysis organizationOctober 22, 2024 | markets.businessinsider.comAkebia Therapeutics Secures Supply Agreement for VafseoOctober 22, 2024 | markets.businessinsider.comAkebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on DialysisOctober 22, 2024 | prnewswire.comAkebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024October 15, 2024 | prnewswire.comMarshall Wace LLP Reduces Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA)Marshall Wace LLP lessened its stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) by 75.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 247,069 shares of the biopharmaceutical company's stock afOctober 12, 2024 | marketbeat.comAkebia Therapeutics (NASDAQ:AKBA) Stock, Insider Trading ActivityOctober 10, 2024 | benzinga.comAkebia Therapeutics (NASDAQ:AKBA) Stock Quotes, Forecast and News SummaryOctober 10, 2024 | benzinga.com Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Media Mentions By Week AKBA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AKBA News Sentiment▼0.870.64▲Average Medical News Sentiment AKBA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AKBA Articles This Week▼153▲AKBA Articles Average Week Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News INDV News AKRO News GLPG News DYN News IMCR News EVO News GPCR News VIR News TVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AKBA) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
